WO2012007555A3 - Nouveaux sels de ziprasidone et leur méthodes de formation - Google Patents

Nouveaux sels de ziprasidone et leur méthodes de formation Download PDF

Info

Publication number
WO2012007555A3
WO2012007555A3 PCT/EP2011/062080 EP2011062080W WO2012007555A3 WO 2012007555 A3 WO2012007555 A3 WO 2012007555A3 EP 2011062080 W EP2011062080 W EP 2011062080W WO 2012007555 A3 WO2012007555 A3 WO 2012007555A3
Authority
WO
WIPO (PCT)
Prior art keywords
ziprasidone
new
formation
methods
salt
Prior art date
Application number
PCT/EP2011/062080
Other languages
English (en)
Other versions
WO2012007555A2 (fr
Inventor
Marek Leszek Glowka
Waldemar Maniukiewicz
Monika Oracz
Lech Swinder
Karol Sagol
Marcin Szulc
Original Assignee
Zaklady Farmaceutyczne Polpharma, S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma, S. A. filed Critical Zaklady Farmaceutyczne Polpharma, S. A.
Publication of WO2012007555A2 publication Critical patent/WO2012007555A2/fr
Publication of WO2012007555A3 publication Critical patent/WO2012007555A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des nouveaux sels de ziprasidone et leurs solvates ont été divulgués, notamment sous forme cristalline. L'invention concerne plus spécifiquement un sel de ziprasidone choisi dans un groupe comprenant succinate de ziprasidone et ascorbate de ziprasidone, un procédé de fabrication du sel de ziprasodine et une composition pharmaceutique comprenant ledit sel.
PCT/EP2011/062080 2010-07-14 2011-07-14 Nouveaux sels de ziprasidone et leur méthodes de formation WO2012007555A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP391810 2010-07-14
PL391810A PL391810A1 (pl) 2010-07-14 2010-07-14 Nowe sole ziprasidonu oraz sposoby ich otrzymywania

Publications (2)

Publication Number Publication Date
WO2012007555A2 WO2012007555A2 (fr) 2012-01-19
WO2012007555A3 true WO2012007555A3 (fr) 2012-03-15

Family

ID=44630161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/062080 WO2012007555A2 (fr) 2010-07-14 2011-07-14 Nouveaux sels de ziprasidone et leur méthodes de formation

Country Status (2)

Country Link
PL (1) PL391810A1 (fr)
WO (1) WO2012007555A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020929A2 (fr) * 2003-09-02 2005-03-10 Imran Ahmed Formes posologiques a liberation prolongee de ziprasidone
WO2005065660A2 (fr) * 2003-12-31 2005-07-21 Alpharma, Inc. Formulations de ziprasidone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0790236T3 (da) 1996-02-13 2004-02-23 Pfizer Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020929A2 (fr) * 2003-09-02 2005-03-10 Imran Ahmed Formes posologiques a liberation prolongee de ziprasidone
WO2005065660A2 (fr) * 2003-12-31 2005-07-21 Alpharma, Inc. Formulations de ziprasidone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *

Also Published As

Publication number Publication date
WO2012007555A2 (fr) 2012-01-19
PL391810A1 (pl) 2012-01-16

Similar Documents

Publication Publication Date Title
AP3346A (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
PL3683209T3 (pl) Sposób wytwarzania kwasu [(5-(3-chlorofenylo)-3-hydroksy-pirydyno-2-karbonylo)amino]octowego z 5-((3-chlorofenylo)-3-chloropirydyn-2-ylo)nitrylu i sposób wytwarzania pochodnych 5-((fluorowcofenylo)-3- fluorowcopirydyno-2-ylo)-nitrylu
IN2014KN00948A (fr)
PL2794600T3 (pl) Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
WO2012122011A3 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
HK1198535A1 (en) 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4] oxazin-3-amine derivatives 5-(3-)-5--5,6--2h-[1,4]-3-
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
WO2011157722A3 (fr) Composition contenant de l'ivabradine solide
WO2010001257A3 (fr) Nouvelles formes à l’état solide de laquinimod et son sel de sodium
WO2012131707A3 (fr) Nouvelle forme cristalline de bortezomib, son procédé de préparation et composition pharmaceutique l'utilisant
WO2010098583A3 (fr) Nouveau procédé de préparation de composés de statine ou des sels de ceux-ci, et composés intermédiaires utilisés dans ce procédé
WO2014049585A3 (fr) Procédé de préparation d'étéxilate de dabigatran ou d'un sel pharmaceutiquement acceptable de cette substance
WO2010039885A3 (fr) Formes cristallines du dexlansoprazole
WO2012116254A3 (fr) Analogues de chrysophaentine qui inhibent la protéine ftsz
EP2742946A4 (fr) Procédé pour la production de dérivés de pyrostegia venusta, dérivés de pyrostegia venusta, compositions pharmaceutiques et leurs utilisations
WO2014049586A3 (fr) Procédé de préparation d'étéxilate de dabigatran ou d'un sel pharmaceutiquement acceptable de cette substance
WO2013088384A3 (fr) Formes à l'état solide d'azilsartan et d'azilsartan médoxomil monopotassique et leur procédé de préparation
EP2634183B8 (fr) Procédé de préparation de 1,3,5-trioxane
WO2013155465A8 (fr) Dérivés de xanthine substituée
EP2575465A4 (fr) Sels de raltégravir
EP2634182B8 (fr) Procédé de préparation de 1,3,5-trioxane
WO2012007555A3 (fr) Nouveaux sels de ziprasidone et leur méthodes de formation
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
WO2013114397A3 (fr) Sel pharmaceutiquement acceptable de brinzolamide et composition de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743469

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11743469

Country of ref document: EP

Kind code of ref document: A2